Through PPI network construction, we predicted that the core biological targets of YTG for IPF treatment were STAT3, SRC, MAPK3, MAPK1, RELA, PTPN11, JUN, MAPK14, STAT1, and EGFR. Here, STAT1 is linked to idiopathic pulmonary fibrosis.